Amgen Stock News

The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK9 Inhibitor to Demonstrate Significant Reduction of Cardiovascular Events as Both Primary and Secondary Prevention THOUSAND OAKS, Calif. , Oct. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today ann...

There are a million and one ways to put your money to work on Wall Street. It might surprise you to learn that investing in dividend growth stocks isn't just one of the easiest; it's also one of the most effective.

In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

Investors love dividend stocks because they offer a significant income stream and have massive total return potential.

THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospects in obesity, type 2 diabetes, and other related indications. I continue to see MariTide's monthly dosing as a strong selling point and expect that addition of dose escalation to phase 3 trial design will improve its tolerability.